ULTRALIFE CORP (ULBI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
---|---|---|---|---|
Revenues | 48,561 | 50,746 | 35,694 | 42,983 |
Cost of products sold | 36,960 | 38,001 | 27,012 | 31,420 |
Gross profit | 11,601 | 12,745 | 8,682 | 11,563 |
Selling, general and administrative | 7,027 | 6,942 | 6,070 | 5,649 |
Research and development | 2,318 | 2,404 | 2,101 | 1,997 |
Total operating expenses | 9,345 | 9,346 | 8,171 | 7,646 |
Operating income | 2,256 | 3,399 | 511 | 3,917 |
Miscellaneous expense (income) | -151 | 79 | 15 | 347 |
Interest and financing expense | 992 | 1,032 | 173 | 418 |
Total other expense | -1,143 | -953 | -158 | -71 |
Income before income taxes | 1,113 | 2,446 | 353 | 3,846 |
Income tax provision | 243 | 567 | 74 | 853 |
Net income | 870 | 1,879 | 279 | 2,993 |
Net income (loss) attributable to non-controlling interest | -9 | 14 | 21 | 24 |
Net income attributable to ultralife corporation | 879 | 1,865 | 258 | 2,969 |
Foreign currency translation adjustments | 875 | 311 | 811 | - |
Comprehensive income attributable to ultralife corporation | 1,754 | 2,176 | 1,069 | 2,969 |
Net income per share attributable to ultralife common stockholders basic (in dollars per share) | 0.05 | 0.02 | 0.02 | 0.21 |
Net income per share attributable to ultralife common stockholders diluted (in dollars per share) | 0.05 | 0.02 | 0.02 | 0.21 |
Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 16,656,000 | 16,680,000 | 16,874,000 | 16,825,000 |
Weighted average shares outstanding basic (in shares) | 16,635,000 | 16,633,000 | 16,625,000 | 16,568,000 |